<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6204">
  <stage>Registered</stage>
  <submitdate>13/05/2015</submitdate>
  <approvaldate>13/05/2015</approvaldate>
  <nctid>NCT02477839</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects =1 Month to &lt; 4 Years With Partial-onset Seizures</studytitle>
    <scientifictitle>A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy &gt;=1 Month to &lt;4 Years of Age With Partial-onset Seizures</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-000717-20</secondaryid>
    <secondaryid>SP0967</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epilepsy With Partial-onset Seizures</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lacosamide
Other interventions - Placebo

Experimental: Lacosamide - Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day

Placebo Comparator: Placebo - Matching placebo syrup


Treatment: drugs: Lacosamide
Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral

Other interventions: Placebo
Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Applicable for the US only if dropout rate is &lt;=10%: The change in average daily frequency (ADF) of electrographic partial-onset seizures - The change in ADF of electrographic partial-onset seizures as measured on the End-of-Maintenance Period video-electroencephalogram (EEG) compared to the End-of-Baseline Period video-EEG</outcome>
      <timepoint>End-of-Baseline Perio to End-of-Maintenance Period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Applicable for the EU and for the US if dropout rate is &gt;10%: Proportion of responders: &gt;= 50% reduction in partial onset seizure frequency from Baseline to the Maintenance Period - The proportion of responders where a responder is a subject experiencing a 50% or greater reduction in their average daily frequency of electrographic partial-onset seizures recorded on the End-of-Maintenance Period video-EEG compared to the End-of-Baseline Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject withdrawals due to Adverse Events (AEs) during the study</outcome>
      <timepoint>From the Titration Period (day 1) to the End of Study Visit (up to 93 days)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of subjects experiencing a &gt;75% reduction in average daily frequency (ADF) of electrographic partial-onset seizures - Proportion of subjects experiencing a &gt;75% reduction in ADF of electrographic partial-onset seizures from the end-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Adverse events reported spontaneously by the subject's parent(s) and/or legal representative(s)/caregiver(s) (in accordance with local regulation) or observed by the investigator</outcome>
      <timepoint>Baseline Period to End-of-Maintenance Period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in average daily frequency (ADF) of electrographic partial-onset seizures - The absolute change in ADF of electrographic partial-onset seizures as measured on the End-of-Maintenance Period video-EEG compared to the End-of-Baseline Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in average daily frequency (ADF) of electrographic partial-onset seizures - The percent change in ADF of electrographic partial-onset seizures as measured on the End-of-Maintenance Period video-EEG compared to the End-of-Baseline Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who achieved "seizure-free" status - Proportion of subjects who achieved "seizure-free" status (yes/no) for subjects who completed at least 48 hours of interpretable video-EEG recording during the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing a &gt;=25% to &lt;50% reduction in average daily frequency (ADF) of electrographic partial-onset seizures - Proportion of subjects experiencing a &gt;=25% to &lt;50% reduction in ADF of electrographic partial-onset seizures from the end-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing a 50% to 75% reduction in average daily frequency (ADF) of electrographic partial-onset seizures - Proportion of subjects experiencing 50% to 75% reduction in ADF of electrographic partial-onset seizures from the end-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing no change in average daily frequency (ADF) of electrographic partial-onset seizures (between &lt;25% reduction and &lt;25% increase) - Proportion of subjects experiencing no change in ADF of electrographic partial-onset seizures (between &lt;25% reduction and &lt;25% increase) from the End-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing an increase in average daily frequency (ADF) of electrographic partial-onset seizures of &gt;=25% - Proportion of subjects experiencing an increase in ADF of electrographic partial-onset seizures of &gt;=25% from the End-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG</outcome>
      <timepoint>End-of-Baseline Period to End-of-Maintenance Period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject is male or female from &gt;=1 month (ie, 4 weeks after full term [37 weeks
             gestational age]) to &lt;4 years of age.

          -  Subject has a diagnosis of epilepsy with partial-onset seizures. The results of &gt;=1
             prior EEG and &gt;=1 magnetic resonance imaging/computerized tomography scan should be
             consistent with this diagnosis.

          -  Subject weighs &gt;=4 kg to &lt;30 kg at Visit 1.

          -  Subject has experienced &gt;=2 partial-onset seizures with or without secondary
             generalization during each consecutive 7-day period during the 2 weeks prior to Visit
             1.

          -  Subject has &gt;=2 partial-onset seizures with or without secondary generalization during
             the End-of-Baseline video-EEG.

          -  Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs.
             The dosage regimen of concomitant AED therapy must be kept constant for a period of
             &gt;=2 weeks prior to Visit 1. A stable daily dosage regimen of a concomitant
             benzodiazepine (BZD) will be considered as a concomitant AED.

          -  Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED.
             The VNS device must have been implanted for &gt;=6 months prior to Visit 1; device
             settings must be kept stable for &gt;=2 weeks prior to Visit 1 and kept stable during the
             Baseline, Treatment, and Transition Periods. Use of the VNS device magnet is allowed.

          -  Subject is an acceptable candidate for venipuncture.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Month</inclusiveminagetype>
    <inclusivemaxage>47</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has experienced febrile seizures exclusively. The occurrence of febrile
             seizures in addition to partial-onset seizures is not exclusionary.

          -  Subject is on a ketogenic diet that has either changed within the 4 weeks prior to
             Visit 1 or is expected to change during the study.

          -  Subject has creatinine clearance &lt;30mL/minute.

          -  Subject has a clinically relevant ECG abnormality, in the opinion of the investigator
             (eg, second or third degree heart block at rest or a corrected QT interval [QTc]
             &gt;=450ms).

          -  Subject has a hemodynamically significant congenital heart disease.

          -  Subject has an arrhythmic heart condition requiring medical therapy.

          -  Subject has a known history of severe anaphylactic reaction secondary to medication
             intake or serious blood dyscrasias.

          -  Subject has nonepileptic events that could be confused with seizures. Subjects may be
             included if epileptic events can be clearly distinguished and the frequency meets the
             study inclusion criteria.

          -  Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis
             continua, primary generalized epilepsy, Dravet Syndorme, or seizures that are not of
             partial-onset origin.

          -  Subject has a history of generalized convulsive status epilepticus &lt;=2 months prior to
             Screening (Visit 1).

          -  Subject has been treated with felbamate and has experienced any serious toxicity
             issues (defined as liver failure, aplastic anemia) with this treatment. Subjects
             treated with felbamate for &lt;12 months are excluded. Subjects treated with felbamate
             for &gt;=12 months prior to Visit 1 and who have not experienced serious toxicity issues
             are eligible.

          -  Subject has an acute or subacutely progressive central nervous system disease. Subject
             has epilepsy secondary to a progressing cerebral disease or any other progressively
             neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome).

          -  Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>244</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sp0967 206 - Clayton</hospital>
    <hospital>Sp0967 203 - Parkville</hospital>
    <hospital>Sp0967 201 - Perth</hospital>
    <hospital>Sp0967 202 - Randwick</hospital>
    <hospital>Sp0967 205 - South Brisbane</hospital>
    <postcode> - Clayton</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Bahia Blanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Niteroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Passo Fundo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changchun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Rijeka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tblisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Radeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>New Hyde Park</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zerifin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Mi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Calambrone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Messina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Salerno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Culiacan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Oaxaca de Juarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Sibiu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Kragujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Beograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Oviedo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnetropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dniepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Uzhgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB BIOSCIENCES, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to assess the effectiveness and the safety of Lacosamide
      administered as add-on therapy with 1 to 3 anti-seizure medications. This trial is for
      children aged 1 month to less than 4 years with epilepsy who currently have uncontrolled
      partial-onset seizures.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02477839</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address>+1 844 599 2273 (UCB)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address />
      <phone>+1 844 599</phone>
      <fax />
      <email>UCBCares@ucb.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>